Summary:
A genomic and transcriptomic study led by the Germans Trias i Pujol Research Institute (IGTP) finds that blood platelets provide a sensitive peripheral window into the molecular evolution of Parkinson’s disease. Published in the journal Movement Disorders, the team followed longitudinal gene expression in a patient with a rare de novo SNCA gene triplication as the illness progressed to dementia over three years.
Isolated platelets revealed substantially stronger transcriptomic changes than whole blood, implicating mitochondrial dysfunction, altered protein translation, and inflammation. Key molecular shifts—including dysregulation of SNCA, YWHAB (14-3-3 family), and MMRN1—were validated in an independent cohort of patients with sporadic early-onset Parkinson’s disease.
Key Facts:
- Platelets outperform whole blood for progression signals: Purified platelets captured disease-associated transcriptomic shifts more clearly than standard whole-blood assays, revealing disruptions in mitochondrial respiration, ribosomal function, and inflammatory pathways.
- Rare SNCA triplication followed longitudinally: Researchers tracked a non-inherited (de novo) 2.41-megabase triplication spanning 21 genes, including SNCA, comparing molecular profiles at age 41 (early motor phase) and age 44 (onset of dementia).
- Findings validated in sporadic Parkinson’s: Several transcript-level changes—such as decreased expression of a specific SNCA isoform and of YWHAB, and increased MMRN1—were confirmed in a separate group of 15 sporadic early-onset Parkinson’s patients versus 18 controls.
Source: Germans Trias i Pujol Research Institute (IGTP)
Monitoring Parkinson’s disease progression in clinical practice remains challenging: clinical scales rely on subjective motor and cognitive assessments and there is a lack of minimally invasive biomarkers that track neurodegenerative velocity or flag early transitions to dementia. Whole-blood transcriptomics has been explored widely, but circulating immune cells and serum components often introduce biological noise that can mask signals originating from the nervous system.
Platelets (thrombocytes) share several functional and molecular properties with neurons: they contain regulated secretory granules, metabolize monoamines such as dopamine and serotonin, express high baseline levels of alpha-synuclein, and maintain active mitochondrial networks—making them a plausible peripheral model for neuronal processes.
Researchers from the Genomics and Transcriptomics of Synucleinopathies (GTS) group at IGTP in Badalona, Spain, therefore evaluated whether platelet RNA profiles could reflect progression-related molecular changes in Parkinson’s disease.
Published in Movement Disorders, the study examined molecular expression across disease stages and identified shared transcriptomic features between an extreme monogenic case and more typical sporadic Parkinson’s patients.
Insights from a De Novo SNCA Triplication
The study, co-led by Katrin Beyer, PhD, and Pau Pastor, MD, PhD, with Susanna Jiménez-Román as first author, focused on a single exceptional case: an individual with early-onset Parkinson’s who progressed rapidly to dementia within three years. Genetic analysis identified a de novo 2.41-megabase triplication on chromosome 4q22.1 that includes SNCA, the gene encoding alpha-synuclein, and 20 other genes.
Because the patient was assessed at two distinct clinical milestones—age 41 (early motor symptoms) and age 44 (after dementia onset)—the team isolated both whole blood and purified platelet fractions at each time point. RNA sequencing and comparative analysis revealed that whole blood showed minimal transcriptomic change between time points, while platelets exhibited a widespread and coherent pattern of dysregulation.
Differentially expressed genes in platelets mapped to core biological processes relevant to Parkinson’s disease:
- Mitochondrial homeostasis: Alterations in electron transport chain components and cellular bioenergetics consistent with impaired mitochondrial function.
- Ribosomal and translational machinery: Broad changes affecting ribosomal proteins and translation factors, indicating disrupted protein synthesis.
- Inflammatory signaling: Activation of pathways linked to systemic and vascular immune responses.
“This unique longitudinal case allowed us to observe how molecular signals shift as Parkinson’s disease progresses. Platelets display clearer changes than whole blood, underscoring their potential as an accessible source of progression biomarkers,” said Susanna Jiménez-Román.
Shared Platelet Signatures in Sporadic Parkinson’s
To test whether the platelet signatures were specific to the rare triplication or reflected broader disease biology, the researchers examined a targeted set of candidate genes in an independent cohort of 15 patients with early-onset sporadic Parkinson’s disease and 18 matched healthy controls.
Platelet profiles in the sporadic group reproduced several findings from the longitudinal case report:
- Reduced SNCA and YWHAB expression: A specific SNCA transcript variant was downregulated alongside YWHAB, which encodes a 14-3-3 protein important for alpha-synuclein binding and cell survival signaling.
- Increased MMRN1: Multimerin-1 (MMRN1), an adhesive protein found in endothelium and platelets, was elevated in patients.
- Upregulation of ribosomal genes: Two genes involved in ribosome assembly showed higher expression, consistent with altered protein synthesis regulation.
After correction for multiple comparisons, these differences remained statistically significant in purified platelets, whereas whole-blood analysis from the same individuals failed to show significant divergence from controls.
Clinical Implications and Future Directions
The overlap between molecular changes in an aggressive monogenic case and those seen in sporadic patients suggests that rare, high-penetrance mutations can illuminate pathogenic pathways shared across the Parkinson’s population. Such shared signatures support the idea that platelets can serve as a minimally invasive source of biomarkers for disease progression and potential cognitive decline.
The authors emphasize that the longitudinal component is limited to a single patient, so the results establish proof-of-concept rather than a validated clinical test. The GTS group plans to expand longitudinal sampling across diverse sporadic cohorts to determine whether platelet RNA signatures can predict cognitive decline or serve as pharmacodynamic markers in forthcoming disease-modifying trials.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by staff.
About this Neuroscience Research:
- Media Contact: Tamara Gutiérrez
- Source: IGTP (Germans Trias i Pujol Research Institute)
- Image Credit: Image credited to Neuroscience News
- Original Research (Open Access): Movement Disorders (Oct 1, 2026). Title: “Severe Parkinson’s Disease Linked to SNCA Locus Triplication Is Associated with Expression Changes in Platelets: A Case Report.” Authors: Susanna Jiménez-Román MSc, David Adamuz MSc, Jorge Mena PhD, Abril Tuset BSc, Mar Mallo PhD, Alex Menendez MD, Daniela Samaniego MD, Lourdes Ispierto MD, PhD, Dolores Vilas MD, PhD, Pau Pastor MD, PhD, Katrin Beyer PhD.
- DOI: 10.1002/mds.70529
Abstract
Severe Parkinson’s Disease Linked to SNCA Locus Triplication Is Associated with Expression Changes in Platelets: A Case Report
Parkinson’s disease is defined by alpha-synuclein aggregation, dopaminergic neuron loss, and chronic neuroinflammation. Growing evidence also points to systemic immune dysregulation. Platelets have emerged as a relevant peripheral model because they share many functional and molecular features with neurons, making platelet transcriptomics a promising avenue for discovering progression biomarkers in Parkinson’s disease.
